David Nachbaur
Overview
Explore the profile of David Nachbaur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1948
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ahmad O, Kroger N, Wagner-Drouet E, Nachbaur D, Steiner N, Teschner D, et al.
Bone Marrow Transplant
. 2025 Mar;
PMID: 40074786
No abstract available.
2.
Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, et al.
Blood Adv
. 2024 Dec;
PMID: 39661985
Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after at least two prior treatment lines, but real-world data is scarce....
3.
Reimann P, Petzer V, Mundlein A, Hartmann B, Severgnini L, Winkler A, et al.
Ann Hematol
. 2024 Mar;
103(6):2123-2131.
PMID: 38436671
Monoclonal antibodies, as tixagevimab/cilgavimab, have been introduced as prophylaxis against COVID-19 infections in high-risk populations. However, data on efficacy are limited. This study investigates efficacy and tolerability of tixagevimab/cilgavimab in...
4.
Czech M, Schneider S, Peltokangas N, El Khawanky N, Ghimire S, Andrieux G, et al.
Sci Transl Med
. 2024 Feb;
16(735):eadi1501.
PMID: 38381845
Acute graft-versus-host disease (aGVHD) is a life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT), for which therapeutic options are limited. Strategies to promote intestinal tissue tolerance during aGVHD may improve...
5.
Dohner H, Weber D, Krzykalla J, Fiedler W, Kuhn M, Schroeder T, et al.
Lancet Haematol
. 2023 May;
10(7):e495-e509.
PMID: 37187198
Background: Acute myeloid leukaemia with mutated NPM1 is associated with high CD33 expression and intermediate-risk cytogenetics. The aim of this study was to evaluate intensive chemotherapy with or without the...
6.
Robin M, Gras L, Koster L, Saccardi R, Finke J, Forcade E, et al.
Bone Marrow Transplant
. 2023 May;
58(8):942-945.
PMID: 37185613
No abstract available.
7.
Steiner N, Gobel G, Mauser L, Muhlnikel L, Fischinger M, Kunz T, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765566
In our single-center study, 357 myeloma and lymphoma patients between 2009 and 2019 were mobilized with granulocyte colony-stimulating factor (G-CSF 7.5 µg/kg bid for four days) plus a fixed dose...
8.
Hudspeth M, Mori S, Nachbaur D, Perez-Simon J, Stolzel F, Riches M, et al.
Haematologica
. 2022 Dec;
108(4):1026-1038.
PMID: 36519326
Acute graft-versus-host disease (aGvHD) is a life-threatening complication typically occurring within 100 days after allogeneic hematopoietic cell transplantation (allo-HCT). This hypothesis-generating, phase II, prospective, open-label, randomized study (clinicaltrials gov. Identifier:...
9.
Steiner N, Schober P, Willenbacher W, Kircher B, Gunsilius E, Wolf D, et al.
Anticancer Res
. 2022 Dec;
42(12):5825-5832.
PMID: 36456157
Background/aim: Despite multiple treatment options, multiple myeloma (MM) remains an incurable disease with poor outcome. Patients And Methods: We retrospectively analyzed the outcome of MM patients undergoing an allogeneic (allo-SCT;...
10.
Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma
Locher M, Jukic E, Vogi V, Keller M, Kroll T, Schwendinger S, et al.
Eur J Haematol
. 2022 Nov;
110(3):296-304.
PMID: 36433728
Long-term disease control in multiple myeloma (MM) is typically an unmet medical need, and most patients experience multiple relapses. Fluorescence in situ hybridization (FISH) is the standard technique to detect...